Q1 Earnings Forecast for LVTX Issued By HC Wainwright

LAVA Therapeutics (NASDAQ:LVTX) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of LAVA Therapeutics in a research report issued on Friday, May 16th. HC Wainwright analyst A. He forecasts that the company will post earnings of ($0.21) per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $1.50 target price on the stock. The consensus estimate for LAVA Therapeutics’ current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for LAVA Therapeutics’ Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.19) EPS and Q4 2026 earnings at ($0.06) EPS.

Separately, JMP Securities reissued a “market perform” rating on shares of LAVA Therapeutics in a report on Thursday, May 15th. Five investment analysts have rated the stock with a hold rating, According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $3.17.

LAVA Therapeutics Stock Up 4.8%

Shares of LVTX stock opened at $1.32 on Monday. The stock has a market cap of $34.72 million, a PE ratio of -1.28 and a beta of 0.46. The business has a 50-day simple moving average of $1.25 and a 200-day simple moving average of $1.24. LAVA Therapeutics has a 52-week low of $0.85 and a 52-week high of $2.81.

LAVA Therapeutics (NASDAQ:LVTX) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.24.

Institutional Investors Weigh In On LAVA Therapeutics

Hedge funds have recently bought and sold shares of the stock. Sanofi acquired a new stake in LAVA Therapeutics in the 4th quarter valued at about $1,825,000. XTX Topco Ltd purchased a new position in shares of LAVA Therapeutics in the 1st quarter valued at about $31,000. Lepercq De Neuflize Asset Management LLC purchased a new position in shares of LAVA Therapeutics in the 1st quarter valued at about $29,000. BML Capital Management LLC purchased a new position in shares of LAVA Therapeutics in the 1st quarter valued at about $2,490,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of LAVA Therapeutics in the 4th quarter valued at about $40,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.